Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population
Maria Benevolo, Pamela Mancuso, Elena Allia, Daniela Gustinucci, Simonetta Bulletti, Elena Cesarini, Francesca Maria Carozzi, Massimo Confortini, Simonetta Bisanzi, Teresa Rubino, Francesca Rollo, Natalina Marchi, Angelo Farruggio, Teresa Pusiol, Francesco Venturelli, Paolo Giorgi Rossi, New Technologies for Cervical Cancer 2 (NTCC2) Working Group, Alessandra Barca, Francesco Quadrino, Maria Benevolo, Francesca Rollo, Paolo Giorgi Rossi, Laura Bonvicini, Pamela Mancuso, Francesco Venturelli, Gabriele Carlinfante, Teresa Rubino, Francesca Maria Carozzi, Simonetta Bisanzi, Massimo Confortini, Carmelina Di Pierro, Giulia Fantacci, Anna Iossa, Karin Louise Andersson, Alessandra Mongia, Giampaolo Pompeo, Cristina Sani, Donella Puliti, Andrea Baldini, Guglielmo Ronco, Raffaella Rizzolo, Anna Gillio Tos, Laura De Marco, Elena Allia, Teresa Pusiol, Mattia Barbareschi, Emma Bragantini, Basilio Passamonti, Daniela Gustinucci, Simonetta Bulletti, Elena Cesarini, Maria Donata Giaimo, Gabriella Penon, Natalina Marchi, Angelo Farruggio, Alessandra Bertazzo, Laura Toniolo, Annarosa Del Mistro, Helena Frayle, Silvia Gori, Manuel Zorzi, Elena Narne, Anna Turrin, Maria Benevolo, Pamela Mancuso, Elena Allia, Daniela Gustinucci, Simonetta Bulletti, Elena Cesarini, Francesca Maria Carozzi, Massimo Confortini, Simonetta Bisanzi, Teresa Rubino, Francesca Rollo, Natalina Marchi, Angelo Farruggio, Teresa Pusiol, Francesco Venturelli, Paolo Giorgi Rossi, New Technologies for Cervical Cancer 2 (NTCC2) Working Group, Alessandra Barca, Francesco Quadrino, Maria Benevolo, Francesca Rollo, Paolo Giorgi Rossi, Laura Bonvicini, Pamela Mancuso, Francesco Venturelli, Gabriele Carlinfante, Teresa Rubino, Francesca Maria Carozzi, Simonetta Bisanzi, Massimo Confortini, Carmelina Di Pierro, Giulia Fantacci, Anna Iossa, Karin Louise Andersson, Alessandra Mongia, Giampaolo Pompeo, Cristina Sani, Donella Puliti, Andrea Baldini, Guglielmo Ronco, Raffaella Rizzolo, Anna Gillio Tos, Laura De Marco, Elena Allia, Teresa Pusiol, Mattia Barbareschi, Emma Bragantini, Basilio Passamonti, Daniela Gustinucci, Simonetta Bulletti, Elena Cesarini, Maria Donata Giaimo, Gabriella Penon, Natalina Marchi, Angelo Farruggio, Alessandra Bertazzo, Laura Toniolo, Annarosa Del Mistro, Helena Frayle, Silvia Gori, Manuel Zorzi, Elena Narne, Anna Turrin
Abstract
Background: The objective of this study was to describe the determinants of adequacy and positivity of the p16/Ki-67 assay in a human papillomavirus (HPV)-positive screening population enrolled within the New Technologies for Cervical Cancer 2 (NTCC2) study.
Methods: ThinPrep slides were immunostained for p16/Ki-67; each slide had 3 reports from different laboratories. The authors included population-related, sampling-related/staining-related, and interpretation-related variables in the analyses. Adequacy and positivity proportions were stratified by variables of interest. Univariate and multivariate logistic models were used to identify determinants of adequacy and positivity.
Results: In total, 3100 consecutive HPV-positive cases were analyzed. Because every slide was interpreted by 3 centers, 9300 reports were obtained, including 905 (9.7%) that were inadequate and 2632 (28.3%) that were positive. The percentage of cases in which all 3 reports were inadequate increased with increasing age of the women and with inadequate cytology. The highest percentage of adequacy in all 3 reports and of cases with all 3 reports positive was observed in specimens from women who had grade ≥2 cervical intraepithelial neoplasia (CIN2+), atypical squamous cells of undetermined significance or more severe (ASC-US+) cytology, or mRNA positivity. The number of inadequate reports was significantly associated with increasing age, inadequate cytology, mRNA negativity, and scant cellularity. A positive p16/Ki-67 report was associated with an ASC-US+ result and with a positive mRNA result in cases both with and without CIN2+ but was associated with an HPV type 16 and/or 18 infection only in CIN2+ cases. The presence of CIN2+ was strongly associated with dual staining positivity.
Conclusions: The interpretation of p16/Ki-67 results may be influenced by several different variables, all of which are part of the steps in the procedure, and by the characteristics of the screened population.
Trial registration: ClinicalTrials.gov NCT01837693.
Keywords: cervical cancer screening; dual immunostaining; human papillomavirus; immunocytochemistry; p16INK4a/Ki-67.
© 2020 American Cancer Society.
References
- Ronco G, Arbyn M, Meijer CJLM, Snijders PJF, Cuzick J. Screening for cervical cancer with primary testing for human papillomavirus. In: Anttila A, Arbyn M, de Vuyst H, et al, eds. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed, suppl. Office for Official Publications of the European Communities; 2015:1-68.
- US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:674-686. doi:10.1001/jama.2018.10897
- Stanczuk GA, Baxter GJ, Currie H, et al. Defining optimal triage strategies for hrHPV screen-positive women-an evaluation of HPV 16/18 genotyping, cytology, and p16/Ki-67 cytoimmunochemistry. Cancer Epidemiol Biomarkers Prev. 2017;26:1629-1635. doi:10.1158/1055-9965.EPI-17-0534
- Wright TC Jr, Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017;144:51-56. doi:10.1016/j.ygyno.2016.10.031
- Ebisch RM, van der Horst J, Hermsen M, et al. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. Mod Pathol. 2017;30:1021-1031. doi:10.1038/modpathol.2017.16
- Wentzensen N, Clarke MA, Bremer R, et al. Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program [published correction appears in JAMA Intern Med. 2019;179:1007]. JAMA Intern Med. 2019;179:881-888. doi:10.1001/jamainternmed.2019.0306
- Allia E, Ronco G, Coccia A, et al. Interpretation of p16(INK4a)/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol. 2015;123:212-218. doi:10.1002/cncy.21511
- Benevolo M, Allia E, Gustinucci D, et al. Interobserver reproducibility of cytologic p16INK4a/Ki-67 dual immunostaining in human papillomavirus-positive women. Cancer Cytopathol. 2017;125:212-220. doi:10.1002/cncy.21800
- Wentzensen N, Fetterman B, Tokugawa D, et al. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol. 2014;122:914-920. doi:10.1002/cncy.21473
- McMenamin M, McKenna M, McDowell A, Dawson C, McKenna R. Intra- and inter-observer reproducibility of CINtec® PLUS in ThinPrep® cytology preparations. Cytopathology. 2017;28:284-290. doi:10.1111/cyt.12426
- Benevolo M, Mancuso P, Allia E, et al. Interlaboratory concordance of p16/Ki-67 dual-staining interpretation in HPV-positive women in a screening population. Cancer Cytopathol. 2020;128:323-332. doi:10.1002/cncy.22248
- Clarke MA, Cheung LC, Castle PE, et al. Five-year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. JAMA Oncol. 2019;5:181-186. doi:10.1001/jamaoncol.2018.4270
- Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18:4154-4162. doi:10.1158/1078-0432.CCR-12-0270
- Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst. 2015;107:djv257. doi:10.1093/jnci.djv257
- Stoler MH, Baker E, Boyle S, et al. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-retrospective insights from ATHENA. Int J Cancer. 2020;146:2599-2607. doi:10.1002/ijc.32669
- Giorgi Rossi P, Bisanzi S, Allia E, et al. Determinants of viral oncogene E6-E7 mRNA overexpression in a population-based large sample of women infected by high-risk human papillomavirus types. J Clin Microbiol. 2017;55:1056-1065. doi:10.1128/JCM.01794-16
- Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119. doi:10.1001/jama.287.16.2114
- Cuzick J, Adcock R, Carozzi F, et al. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. Int J Cancer. 2020;147:1864-1873. doi:10.1002/ijc.32973
Source: PubMed